Exact Mass: 481.065473
Exact Mass Matches: 481.065473
Found 43 metabolites which its exact mass value is equals to given mass value 481.065473,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N-(2,2,2-Trifluoroethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}benzenesulfonamide
C17H12F9NO3S (481.0394150000001)
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].
T0901317
C17H12F9NO3S (481.0394150000001)
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].
6-(Methylsulfonyl)hexyl glucosinolate
6-(Methylsulfonyl)hexyl glucosinolate is present in crucifers. Present in crucifers
Glucomalcomiin
Acquisition and generation of the data is financially supported by the Max-Planck-Society
2-(4-Methoxyphenyl)-2,2-dimethylethyl glucosinolate
C18H27NO10S2 (481.10763219999995)
6-Hydroxydelphinidin 3-glucoside
4-(3-Chloro-2-cyanophenoxy)-N-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]benzenesulfonamide
C23H16ClN3O3S2 (481.03215760000006)
6-(Methylsulfonyl)hexyl glucosinolate
silybin (mixture of silybin a and silybin b)
C25H21O10 (481.11346660000004)
Diethyl thiophosphoryl-(Z)-2-(2-aminothiazol-4-yl)-2-(tert-butoxycarbonyl)isopropoxyiminoacetate
C17H28N3O7PS2 (481.11062280000004)
4-METHYLUMBELLIFERYL-2-ACETAMIDO-2-DEOXY-6-SULPHATE-β-D-GLUCOPYRANOSIDE
4-(3,5-Dimethylphenoxy)-5-(furan-2-ylmethylsulfanylmethyl)-3-iodo-6-methylpyridin-2(1H)-one
C20H20INO3S (481.0208600000001)
Imidazol-3-ide;2-pyridin-2-ylpyridine;ruthenium(3+)
3-Amino-4-hydroxybenzoate-adenylate
C17H18N6O9P- (481.0872848000001)
N-[1-[(4-bromoanilino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide
4-[[1-[(3,4-Dichlorophenyl)methyl]-3-indolyl]-(3-methyl-5-oxo-1,2-dihydropyrazol-4-yl)methyl]-5-methyl-1,2-dihydropyrazol-3-one
N-[3-[(2,4-dimethylphenyl)sulfamoyl]-4-methylphenyl]-3-oxo-4H-1,4-benzothiazine-6-carboxamide
C24H23N3O4S2 (481.11299180000003)
5-bromo-2-methoxy-3-methyl-N-[4-(4-methylsulfonyl-1-piperazinyl)phenyl]benzamide
C20H24BrN3O4S (481.06708040000007)
N-(4-methoxyphenyl)sulfonyl-N-(2-oxo-5-benzo[g][1,3]benzoxathiolyl)-2-furancarboxamide
Ethyl 4,5-dimethyl-2-[[2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)acetyl]amino]thiophene-3-carboxylate
C24H23N3O4S2 (481.11299180000003)
N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-phenyl-2-thiophenesulfonamide
N-[[3-bromo-4-[(4-fluorophenyl)methoxy]-5-methoxyphenyl]methyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanamine
C19H21BrFN5O2S (481.05832780000003)
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-methoxybenzoate
C18H20N5O9P (481.0998600000001)
AGI-6780
C21H18F3N3O3S2 (481.07416340000003)
AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
SB-399885 hydrochloride
C18H22Cl3N3O4S (481.0396542000001)
SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
UC2288
C20H18ClF6N3O2 (481.09916699999997)
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].